MAPT and Cognitive impairment: Our analysis revealed that, in patients with cognitive impairment due to AD, (i) sPECAM-1, sP-, sE-Selectins, and IL6 were associated with amyloid and tau pathology; (ii) sP-Selectin, sNCAM, and the decrease of IL10 with neurodegeneration; and (iii) LPS and IL1β with cognitive impairment.